推薦產(chǎn)品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 中草藥因中國(guó)經(jīng)濟(jì)轉(zhuǎn)型而產(chǎn)量減少，加上各國(guó)爭(zhēng)相購買，道地藥材價(jià)格飆漲。
馬來西亞媒體報(bào)道，柔南中醫(yī)藥業(yè)公會(huì)會(huì)長(zhǎng)蕭國(guó)津指出，隨著中國(guó)近期進(jìn)一步加強(qiáng)管制規(guī)范中藥加工，加上令吉持續(xù)疲軟，導(dǎo)致業(yè)者成本增加，當(dāng)?shù)厮幉钠毡樯蠞q20%至30%，一些藥材的價(jià)格甚至上漲到一倍以上。
本地的中醫(yī)師與中藥業(yè)者告訴《新明日?qǐng)?bào)》，中藥材價(jià)格逐年上漲的主因包括中國(guó)經(jīng)濟(jì)轉(zhuǎn)型，藥材產(chǎn)量減少，加上全球各國(guó)爭(zhēng)著買，需求增加而推高價(jià)格等。此外，我國(guó)對(duì)藥材進(jìn)口管制嚴(yán)格，貨源得經(jīng)認(rèn)證篩選，由于來源受限，在價(jià)格方面雖沒有彈性，但卻能保證質(zhì)量與安全。
中醫(yī)師王邦旺說，幾乎所有藥材的價(jià)格幾年來都持續(xù)上漲，尤其是道地的藥材，價(jià)格比其他地區(qū)種植的要貴數(shù)倍?！耙曰瓷絹碚f，廣西的一公斤六七元，但鐵棍的道地淮山卻要20元。中醫(yī)對(duì)藥材來源地很講究，其土壤、陽光等都會(huì)影響品質(zhì)，移種的都不能相比?！?/p>
新加坡中藥公會(huì)副主席黃先生指出，一些如五味子等的價(jià)格因人工成本而猛漲，其他如當(dāng)歸等則可能因氣候影響收成而起價(jià)。此外，有時(shí)候傳出某中藥材有奇效的傳聞時(shí)，也會(huì)導(dǎo)致這些藥材突然漲價(jià)。
